Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Drug licensed for pulmonary arterial hypertension

  • Comment

A new treatment option for patients with pulmonary arterial hypertension has been launched in England.

Macitentan (Opsumit) is a novel endothelin receptor antagonist indicated for the long-term treatment of pulmonary arterial hypertension in adults.

Pulmonary arterial hypertension is a severe, life-threatening disorder with around 3,000 people in England on disease-targeted drug therapy, according to the 2013 National Audit of Pulmonary Hypertension.

It is characterised by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual.

Macitentan, which is manufactured by Actelion Pharmaceuticals, received EU marketing authorisation on 20 December 2013, following completion of the SERAPHIN study − the longest and largest clinical trial to date in pulmonary arterial hypertension.

Results from the trial were published last year in the New England Journal of Medicine.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.